We would love to hear your thoughts about our site and services, please take our survey here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMolten Ventures Regulatory News (GROW)

Share Price Information for Molten Ventures (GROW)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 233.50
Bid: 234.50
Ask: 236.00
Change: -6.50 (-2.71%)
Spread: 1.50 (0.64%)
Open: 237.00
High: 240.00
Low: 232.50
Prev. Close: 240.00
GROW Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

New Investments

7 Feb 2018 07:00

RNS Number : 1152E
Draper Esprit PLC
07 February 2018
 

Strictly embargoed until: 07.00 on 7th February 2018

 

Draper Esprit plc

("Draper Esprit" or the "Company")

 

DRAPER ESPRIT INVESTS IN THREE NEW INNOVATIVE TECH COMPANIES

EVONETIX, DROPLET COMPUTING AND KAPTIVO RAISE A COMBINED TOTAL OF £15.2 MILLION

 

Draper Esprit (AIM: GROW, ESM: GRW), a leading venture capital firm investing in and developing high growth digital technology businesses, announces that funds managed by the Group have recently committed a total of £6.6 million into three exciting new European based digital technology businesses: Evonetix, Droplet Computing and Kaptivo.

 

In aggregate, these companies have recently completed fundraising rounds totalling over £15.2 million.

 

About the three investments:

 

Evonetix was founded in 2016 in Cambridge to develop technology that enables the parallel synthesis of DNA on silicon arrays, to facilitate the fast-emerging field of synthetic biology, where there is increasing demand for high throughput and highly accurate DNA synthesis. The company's platform uses an addressable silicon array to direct the synthesis of DNA at many sites in parallel, followed by an error-detection process to allow the assembly of high-fidelity DNA at scale. Evonetix's platform offers the prospect of synthesising DNA sequences accurately without limitation of size, potentially transforming the world of synthetic biology by enabling scientists to engineer the next generation of medicines, as well as improved versions of products currently used every day.

 

Evonetix completed a Series A round co-led by Draper Esprit and Silicon Valley based investor DCVC (Data Collective) and including among others Hermann Hauser, the Cambridge-based scientist and entrepreneur.

 

Droplet Computing founded in 2014 in Kidderminster, is redefining application delivery with its patent-pending application container technology, enabling applications to be delivered on any device. Today's businesses are under pressure to transform and update but are being held back by applications - from legacy up to current versions. Droplet Computing decouples applications from the OS for online and offline use and delivers significant business value by providing costs savings and to user productivity.

 

Kaptivo is a Cambridge based company bringing analog whiteboards into the digital enterprise collaboration space. Kaptivo's mission is to enhance collaboration by providing a bridge between the physical and digital worlds. Their products provide whiteboard live streaming and image capture for enterprise and education markets. Kaptivo develops and applies leading-edge optical technology, image processing, and embedded computer vision software. Kaptivo has offices in Silicon Valley, California, and Cambridge in the UK.

 

Kaptivo recently completed a round of financing with Draper Esprit investing alongside Benhamou Global Ventures and Generation Ventures. With the new funding, Kaptivo will expand its global presence through channel and strategic partnerships, accelerate product development, as well as adding further world-class talent to its team.

 

Simon Cook, CEO at Draper Esprit commented:

 

"Draper Esprit continues to lead the way in UK and European tech funding. From synthetic biology, to productivity in the office and the educational environment, these three recent investments are great examples of emerging businesses that utilise their technology to transform the markets in which they operate. All have the potential to become global leaders and we look forward to providing further expertise and capital support to enable them to scale quickly."

 

*ends*

 

For further information, please contact:

Draper Esprit plc

Simon Cook (Chief Executive Officer)

Ben Wilkinson (Chief Financial Officer)

 

+44 (0)20 7931 8800

 

Numis Securities

Nominated Adviser & Joint Broker

Alex Ham

Richard Thomas

Jamie Loughborough

Harry Trueman

 

+44 (0)20 7260 1000

Goodbody Stockbrokers

ESM Adviser & Joint Broker

Don Harrington

Linda Hickey

Charlotte Craigie

Richard Tunney

 

 +353 1 667 0420

Belvedere Communications (PR)

John West

Kim van Beeck

+44 (0)20 3567 0510

 

About Draper Esprit

Draper Esprit is one of the most active venture capital firms in Europe, developing and investing in disruptive, high growth technology companies. We believe the best entrepreneurs in Europe are capable of building the global businesses of the future. We fuel their growth with long- term capital, access to international networks and decades of experience building businesses. Currently Draper Esprit is a shareholder in a diverse portfolio of companies including Trustpilot, Graze, Perkbox, PushDoctor and Graphcore.

Visit www.draperesprit.com

About Droplet

 

Droplet Computing is redefining application delivery with its patent-pending application container technology, enabling applications to be delivered on any device. Today's businesses are under pressure to transform and update but are being held back by applications - from legacy up to current versions. Droplet Computing decouples applications from the OS for online and offline use and delivers significant business value by providing costs savings, to user productivity and beyond.

 

Learn more at www.dropletcomputing.com or follow us on Twitter @dropletcom.

 

About Evonetix Ltd

 

Evonetix is developing a novel, highly disruptive approach to gene synthesis, the technology which underpins the rapidly growing field of synthetic biology. The Company was co-founded in 2016 by breakthrough innovation specialists Cambridge Consultants Ltd and Providence Investment Company Limited with key staff from next-generation sequencing company Solexa. Its executive management team has many years' experience in the development and delivery of successful biotech ventures.

 

There are two key components of the Evonetix approach: (i) a highly scalable platform, with up to 10,000 sites for DNA synthesis, at each of which there is independent, exquisite control of the synthesis process; and (ii) the ability to assemble DNA molecules with a very low error rate using a process of error detection throughout assembly. In addition, the approach will permit the synthesis of 'difficult' sequences, such as those with a high GC content or with repeats.

 

The company's technology is based upon a novel silicon array, manufactured with semiconductor microfabrication techniques and permitting the independent control required at the miniaturised reaction sites. This will allow massive parallelism in the DNA synthesis process and therefore very high throughput. The approach will be suitable for the large-scale projects of synthetic biology.

 

For further information see www.evonetix.com.

 

About Kaptivo

 

Kaptivo's mission is to enhance collaboration by providing a bridge between the physical and digital worlds. Their products provide whiteboard live streaming and image capture for enterprise and education markets. Kaptivo develops and applies leading-edge optical technology, image processing, and embedded computer vision software. Kaptivo has offices in Silicon Valley, California, and Cambridge, UK. Kaptivo is the trading name of Light Blue Optics.

 

For more information, please visit www.kaptivo.com.

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCFKADBFBKDFBK
Date   Source Headline
23rd Apr 20245:55 pmEQSMolten Ventures Plc: HOL-Holding(s) in Company*
23rd Apr 20247:00 amEQSFull year trading update and notice of results
19th Apr 20245:55 pmEQSMolten Ventures Plc: HOL-Holding(s) in Company
2nd Apr 20247:00 amEQSMolten Ventures Plc: TVR-Total Voting Rights
20th Mar 20247:00 amEQSMolten Ventures Plc: HOL-Holding(s) in Company
18th Mar 20245:55 pmEQSMolten Ventures Plc: HOL-Holding(s) in Company*
18th Mar 202410:51 amRNSForm 8.5 (EPT/NON-RI) - Molten Ventures
18th Mar 20247:00 amRNSPerkbox Exit
15th Mar 20242:36 pmRNSForm 8.3 - Molten Ventures PLC
15th Mar 202411:51 amRNSForm 8.3 - Molten Ventures plc
15th Mar 202411:08 amRNSForm 8.5 (EPT/NON-RI) - Molten Ventures
14th Mar 20243:00 pmRNSForm 8.3 - Molten Ventures Plc
14th Mar 20242:00 pmRNSForm 8.3 - Molten Ventures plc
14th Mar 20241:28 pmEQSForm 8.3 - The Vanguard Group, Inc.: Molten Ventures plc
14th Mar 20241:00 pmEQSMolten Ventures Plc: Completion of Acquisition, Admission of New Molten Shares and Total Voting Rights
14th Mar 202411:40 amRNSForm 8 (DD) - Molten Ventures plc
14th Mar 202410:52 amRNSForm 8.5 (EPT/NON-RI) - Molten Ventures plc
14th Mar 202410:50 amRNSForm 8.5 (EPT/RI) - Molten Ventures Plc
14th Mar 20249:13 amRNSForm 8.5 (EPT/RI)
14th Mar 20248:30 amRNSScheme Effective
13th Mar 20241:42 pmRNSForm 8.3 - Molten Ventures Plc
13th Mar 202411:54 amRNSForm 8.5 (EPT/RI) - Molten Ventures Plc
13th Mar 202410:26 amRNSForm 8.5 (EPT/RI)
13th Mar 20249:30 amRNSForm 8.5 (EPT/NON-RI) - Molten Ventures plc
12th Mar 20243:02 pmRNSForm 8.3 - Molten Ventures PLC
12th Mar 20242:46 pmRNSForm 8.3 -MOLTEN VENTURES PLC
12th Mar 202412:21 pmRNSCourt Sanction of the Scheme
12th Mar 202411:55 amRNSForm 8.5 (EPT/RI) - Molten Ventures Plc
12th Mar 202411:40 amRNSForm 8 (DD) - Molten Ventures plc
12th Mar 202410:06 amRNSForm 8.5 (EPT/NON-RI) - Molten Ventures
12th Mar 20249:37 amRNSInvestor Presentation on Forward Partners
12th Mar 20249:00 amEQSInvestor Presentation on Forward Partners
12th Mar 20248:46 amRNSForm 8.5 (EPT/RI)
11th Mar 20243:17 pmEQSForm 8.3 - The Vanguard Group, Inc.: Molten Ventures plc
11th Mar 20241:38 pmRNSForm 8.3 - Molten Ventures Plc
11th Mar 202411:40 amRNSForm 8 (DD) - Molten Ventures plc
11th Mar 202411:05 amRNSForm 8.5 (EPT/RI) - Molten Ventures Plc
11th Mar 20249:39 amRNSForm 8.5 (EPT/NON-RI) - Molten Ventures
11th Mar 20249:14 amRNSForm 8.5 (EPT/RI)
8th Mar 20242:19 pmRNSForm 8.3 - Molten Ventures plc
8th Mar 202411:40 amRNSForm 8 (DD) - Molten Ventures plc
8th Mar 202411:05 amRNSForm 8.3 - Molten Ventures PLC
8th Mar 202410:13 amRNSForm 8.5 (EPT/RI) - Molten Ventures Plc
8th Mar 202410:11 amRNSForm 8.5 (EPT/RI)
8th Mar 20249:49 amRNSForm 8.5 (EPT/NON-RI) - Molten Ventures
7th Mar 20245:55 pmRNSMolten Ventures
7th Mar 20242:46 pmRNSForm 8.3 - Molten Ventures plc
7th Mar 20241:31 pmRNSForm 8.3 - Molten Ventures PLC
7th Mar 202412:43 pmRNSForm 8.3 - Molten Ventures plc
7th Mar 202411:40 amRNSForm 8 (DD) - Molten Ventures plc

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.